Qiagen NVHorizion EuropePharmahungary Group participates in ambitious EU EVEREST Project Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next … more ➔
Alentis TherapeuticsFinancingAlentis Therapeutics raises US$181.4m in Series D financingSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours. more ➔
BIOCOMPEGS Europe 2024Next-gen antibody formats presented at PEGS EuropeBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several … more ➔
Memorial Sloan Kettering Cancer CentreEarly cancer detectionHarbinger Health to speed up clinical cancer test validationUS spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study … more ➔
Novo NordiskCollaborationNovo Nordisk signs deal for monthly GLP-1 agonistNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing … more ➔
ProBioGenCancer vaccinesTransgene and ProBioGen forge partnershipThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccine … more ➔
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038Novo NordiskNovo’s obesity blockbuster semaglutide before label extensionIn both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity bloc … more ➔
© Niclas Jessen Studio/Bracco Imaging SpAFinancingBlue Therapeutics gets financing to push radiotherapiesRadiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) … more ➔
EniferNovel FoodEnifer files for EFSA authorisation of mycoproteinAs the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA. more ➔
Knowledge Seeker - wikipedia.orgDigital PathologyAIgnostics raises US$34m in Series B financingDigital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and … more ➔
Qiagen NV
Alentis Therapeutics
BIOCOM
Memorial Sloan Kettering Cancer Centre
Novo Nordisk
ProBioGen
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038
© Niclas Jessen Studio/Bracco Imaging SpA
Enifer
Knowledge Seeker - wikipedia.org